Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.-Reference-Cited by-同舟云学术

Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:3519-3519
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Loupakis Fotios¹,Cremolini Chiara²,Lonardi Sara³,Tomasello Gianluca⁴,Ronzoni Monica⁵,Zaniboni Alberto⁶,Tonini Giuseppe⁷,Valsuani Chiara⁸,Chiara Silvana⁹,Boni Corrado¹⁰,Marcucci Lorenzo¹¹,Negri Francesca¹²,Barone Carlo¹³,Vitello Stefano¹⁴,D'Amico Mauro¹⁵,Granetto Cristina¹⁶,Fontanini Gabriella¹⁷,Tomcikova Daniela¹⁸,Boni Luca¹⁹,Falcone Alfredo²

Affiliation:

1. U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

2. U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy

3. Medical Oncology 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

4. Istituti Ospitalieri di Cremona, Cremona, Italy

5. Dipartimento di Oncologia Medica, Istituto Scientifico San Raffaele, Milano, Italy

6. Department of Medical Oncology, Casa di Cura Poliambulanza, Brescia, Italy

7. Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy

8. U.O. Oncologia Medica, Ospedale Versilia, Viareggio, Italy

9. Medical Oncology Unit, National Cancer Institute, Genoa, Italy

10. “S. Maria Nuova” Hospital, Reggio Emilia, Italy

11. Division of Medical Oncology, USL 5 Pontedera, Pontedera, Italy

12. Medical Oncology Unit, University Hospital of Parma, Parma, Italy

13. Catholic University, Rome, Italy

14. U.O. Oncologia, Ospedale Sant'Elia, Caltanissetta, Italy

15. E. O. Ospedali Galliera, Genoa, Italy

16. U.O. Oncologia Medica, Azienda Sanitaria Ospedaliera S. Croce e Carle, Cuneo, Italy

17. Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

18. Istituto Toscano Tumori, Florence, Italy

19. Clinical Trial Coordinating Center, AOU Careggi, Istituto Toscano Tumori (ITT), Firenze, Italy

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.3519

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancers colorectaux avec mutation V600E de BRAF : où en sommes-nous ?;Bulletin du Cancer;2020-09

2. Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients;The Oncologist;2019-05-31

3. New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer;Current Oncology Reports;2016-02-10

4. Genomic diversity of colorectal cancer: Changing landscape and emerging targets;World Journal of Gastroenterology;2016

5. BRAF in metastatic colorectal cancer: the future starts now;Pharmacogenomics;2015-12